Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more
Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.
How this was made
The 30-second read
Why it matters
The article provides fresh corporate data (earnings beats, guidance updates, court rulings) that were not previously reported, offering traders actionable insights into price direction.
Market read
Multiple large‑cap and mid‑cap stocks experienced significant intraday moves due to fresh earnings and legal news, making the roundup highly relevant for short‑term traders.
What to watch
The long‑term Amazon‑Constellation deal could signal broader utility‑tech collaborations not yet priced in.
Background
A midday market roundup highlighting the biggest price moves driven by earnings, guidance, legal rulings, and strategic partnerships.
Ticker impact
Accenture reported Q4 revenue of $18.7B beating guidance and consensus, driving an 18% mid‑day surge.
likely upside as market prices in the earnings beat
Revenue and EPS both exceeded expectations, prompting a sharp rally.
McCormick posted Q3 earnings of $0.86 EPS beating $0.76 consensus, but shares fell over 2% amid pending Unilever acquisition.
mixed pressure from earnings beat versus acquisition concerns
Positive earnings are outweighed by market skepticism on the takeover.
McKesson reaffirmed FY2027 EPS guidance, sending shares 4% higher ahead of its Q2 report on Nov 4.
likely modest upside as investors value the guidance stability
Guidance lift reinforces earnings outlook.
A Delaware court ruled that Liquidia infringed a United Therapeutics patent; BTIG upgraded United Therapeutics to buy, sending it up 6%.
likely upside as the ruling clears growth path
The favorable ruling removes a major risk to United Therapeutics.
Liquidia was downgraded to neutral after the patent infringement ruling, causing a 15% drop.
likely downside as product launch prospects dim
The court decision restricts Liquidia's ability to market Yutrepia.
Constellation Energy announced a 20‑year power‑plant deal with Amazon, lifting shares nearly 3%.
likely modest upside as the deal adds revenue visibility
A multi‑decade agreement signals stable future cash flow.
Synopsys jumped >8% after its investor day outlined 2027 revenue growth of 15% and announced a strategic partnership with OpenAI.
likely upside as investors price in higher growth and AI exposure
Guidance above consensus and AI tie‑up are strong catalysts.
Acuity Brands dropped nearly 4% after guidance for net‑sales growth fell short of consensus expectations.
likely downside as growth outlook disappoints investors
Lower‑than‑expected sales growth guidance reduces optimism.
Market effects
Technology and healthcare earnings beats lift sector sentiment; legal setbacks weigh on biotech and mining.
U.S. equities see mixed moves as earnings and legal news dominate mid‑day trading.
Limited to U.S. markets; no direct macro or geopolitical impact.
Counterpoint
Some stocks (e.g., McCormick) may be oversold despite earnings beat due to acquisition uncertainty.
Key entities
- companyAccenture
Professional services firm with strong Q4 earnings beat.
- companySynopsys
EDA software provider announcing growth guidance and OpenAI partnership.
- companyUnited Therapeutics
Biotech firm winning a patent infringement case.
